Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Sep 8;9(9):CD013672.
doi: 10.1002/14651858.CD013672.pub2.

Opioid agonist therapy for opioid use disorder in primary versus specialty care

Danielle Perry  1 , Jessica Em Kirkwood  2   3 , Marissa L Doroshuk  3 , Michael Kelmer  3 , Christina S Korownyk  3 , Joey Ton  4 , Scott R Garrison  3
Affiliations
Meta-Analysis

Opioid agonist therapy for opioid use disorder in primary versus specialty care

Danielle Perry et al. Cochrane Database Syst Rev. .

Abstract

Background: Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small. One initiative to improve the access and uptake of OAT could be to offer OAT in a primary care setting; primary care clinics are more numerous, might reduce the visibility and potential stigma of receiving treatment for OUD, and may facilitate the care of other medical conditions that are unrelated to OUD. However, it is unknown how effective treating OUD in primary care would be.

Objectives: To assess the benefits and harms of using opioid agonist therapy (OAT) to treat people with opioid use disorder (OUD) in a primary care setting, as compared to a traditional specialty care setting.

Search methods: We searched the Cochrane Drugs and Alcohol Group Specialized Register, Cochrane Central Register of Controlled Trials, MEDLINE, Embase, three other databases, and two trials registers in March 2025. We did not restrict searches by language or publication date.

Selection criteria: Eligible studies were parallel randomized controlled trials (RCTs) and cluster-randomized trials comparing OAT for OUD treatment in primary care versus specialty care settings. Participants were community-dwelling adults with OUD, as identified and defined by trial-specific inclusion criteria. We excluded trials if they included only pregnant women, or those who were incarcerated, but accepted all other comorbidity requirements (e.g. being HIV positive).

Data collection and analysis: Primary outcomes included treatment retention, abstinence from non-prescribed opioids, major adverse events, and withdrawals due to adverse events. Secondary outcomes were other patient-oriented outcomes, including quality of life, patient satisfaction, all-cause mortality, opioid-related mortality, all-cause hospitalization or emergency room visit, all-cause incarceration, and minor adverse events. Two review authors independently extracted data using a predesigned RCT template in Covidence. We assessed risk of bias using the Cochrane RoB 1 tool, and certainty of evidence using GRADE. We analyzed outcomes using Review Manager and a random-effects model to account for variability in care models and populations.

Main results: We included seven RCTs involving 1992 participants. The studies were completed in France (1 study), Ukraine (1 study), and the US (5 studies), and enrolled predominantly males (75%) with a mean age of 38 years. Risk of bias in individual trials was typically low or unclear in all domains except for blinding, where it was high, given participants and providers could not realistically be blinded to setting. One trial was at high risk of bias related to random sequence generation and another for incomplete outcome data. The evidence is very uncertain whether there was a difference in treatment retention in a primary care setting (risk ratio (RR) 1.15, 95% confidence interval (CI) 0.98 to 1.34; 7 studies, 1952 participants; very low-certainty evidence). Abstinence from non-prescribed opioids at the end of follow-up may have been higher in participants managed in primary care (RR 1.59, 95% CI 1.03 to 2.46; 5 studies, 428 participants; low-certainty evidence). Major adverse events were infrequently reported. Only one trial reported all-cause death (one in primary care versus four in specialty care), but these numbers were too small to be meaningful (very low-certainty evidence). Although data from three studies regarding patient satisfaction could not be combined, patients in primary care may have had greater satisfaction. We downgraded certainty in the evidence twice for indirectness for all outcomes given the studies excluded high-risk patients (e.g. those who were pregnant, had co-dependence on alcohol or benzodiazepines, had psychiatric illness, or were homeless) and primary care providers were often atypical of primary care in general (with connections to, or proximity with, OUD-specialized clinics). We downgraded treatment retention an additional level for inconsistency due to high heterogeneity (I2 = 69%).

Authors' conclusions: For lower-risk people with OUD who were stable on OAT, managing their OAT in primary care, as compared to specialty care, the evidence is very uncertain for treatment retention and may have resulted in better abstinence from non-prescribed opioids and better patient satisfaction. Further trials in primary care clinics that have less experience with, or connection to, OUD specialty clinics is warranted.

Trial registration: ClinicalTrials.gov NCT00657397.

PubMed Disclaimer

Conflict of interest statement

DP is a Clinical Evidence Expert at the College of Family Physicians of Canada. She declares honoraria from non‐profit organizations for speaking events at Northern Health Continuing Professional Development, and Making Evidence Matter for Everyone (conference); all personal payments.

JK is a Full Scope Family Physician at Radius Community Health and Healing and an Assistant Professor at the University of Alberta. She declares honoraria and travel expenses from 1. the Alberta College of Family Physicians, for teaching a series of workshops on the treatment of opioid use disorder, and 2. The College of Family Physicians of Canada, for a webinar on treating opioid use disorder; both personal payments.

MD is a Research Administrative Co‐ordinator at the University of Alberta.

MK is a Registered Nurse. He works as a Research Assistant at the University of Alberta, and does casual work at a corrections healthcare facility and a live‐in residential addictions and mental health treatment center.

CK is a Full Scope Family Physician and Professor at the University of Alberta.

JT as a Program Manager, Knowledge Experts and Tools, at The College of Family Physicians of Canada.

SG is a practicing Family Physician. A small proportion of his patients, representative of the proportion in the population at large, will have opioid use disorder.

Update of

  • doi: 10.1002/14651858.CD013672

References

References to studies included in this review

Carrieri 2014 {published data only}
    1. Carrieri P, Laurent M, Lions C, Cohen J, Vray M, Mora M, et al. Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville). PLOS One 2014;9(11):e112328.
    1. NCT00657397. Initialization of methadone in primary care, randomized intervention research for preventing HCV transmission practices (Methaville) [Initialization of methadone in primary care; a randomized intervention research for preventing HCV transmission practices. ANRS Methaville]. https://clinicaltrials.gov/study/NCT00657397 (first posted 14 April 2008).
Fiellin 2001 {published data only}
    1. Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. JAMA 2001;286(14):1724-31.
King 2006 {published data only}
    1. King V, Kidorf M, Stoller K, Schwartz R, Kolodner K, Brooner R. A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. Journal of Substance Abuse Treatment 2006;31(4):385-93.
Lucas 2010 {published data only}
    1. Lucas G, Chaudhry A, Hsu J, Woodson T, Lau B, Olsen Y, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial. Annals of Internal Medicine 2010;152(11):704-11.
Machavariani 2024 {published and unpublished data}
    1. Machavariani E, Dumchev K, Pykalo I, Filippovych M, Ivasiy R, Esserman D, et al. Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine. Contemporary Clinical Trials 2024;146:107690. [PMID: ] - PMC - PubMed
    1. Pashchenko O, Bromberg DJ, Dumchev K, LaMonaca K, Pykalo I, Filippovych M, et al. Preliminary analysis of self-reported quality health indicators of patients on opioid agonist therapy at specialty and primary care clinics in Ukraine: a randomized control trial. PLOS Global Public Health 2022;2(11):e0000344.
O'Connor 1998 {published data only}
    1. O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. American Journal of Medicine 1998;105(2):100-5.
Tuchman 2006 {published data only}
    1. Tuchman E, Gregory C, Simson M, Drucker E. Safety, efficacy, and feasibility of office-based prescribing and community pharmacy dispensing of methadone. Addictive Disorders and Their Treatment 2006;5(2):43-51.

References to studies excluded from this review

Bevanda 2017 {published data only}
    1. Bevanda D, Tomić I, Bevanda M, Skočibušić S, Palameta N, Martinac M. The differences in quality of life between the heroin addicts treated in methadone program and addicts treated in the Frame of Therapeutic Community Program. Alcohol and Psychiatric Research 2017;53:17-26.
Doran 2004 {published data only}
    1. Doran CM, Shanahan M, Bell J, Gibson A. A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal. Drug and Alcohol Review 2004;23(2):171-5.
Fiellin 2002 {published data only}
    1. Fiellin DA, O'Connor PG, Chawarski M, Pantalon MP, Schottenfeld RS. Office versus narcotic treatment program-based buprenorphine for opioid dependence. Drug and Alcohol Dependence 2002;66:55-6.
Gibson 2003 {published data only}
    1. Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: a randomized trial. Medical Journal of Australia 2003;179:38-42.
ISRCTN58665373 {unpublished data only}
    1. ISRCTN58665373. Methadone maintenance treatment for opiate addicts in shared care: is it effective in improving health outcomes and reducing criminality? A randomized controlled trial in a new primary care clinic. https://www.isrctn.com/ISRCTN58665373 (first posted 23 January 2004).
Jones 2007 {published data only}
    1. Jones ES, Fiellin DA. Women and opioid dependence treatment: office-based versus opioid treatment program-based care. Substance Abuse 2007;28:3-8.
Jutras‐Aswad 2022 {published data only}
    1. Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Bruneau J, Fischer B, et al. Flexible buprenorphine/naloxone model of care for reducing opioid use in individuals with prescription-type opioid use disorder: an open-label, pragmatic, noninferiority randomized controlled trial. American Journal of Psychiatry 2022;179(10):726-39.
Marcovitz 2021 {published data only}
    1. Marcovitz DE, White KD, Sullivan W, Limper HM, Dear ML, Buie R, et al. Bridging recovery initiative despite gaps in entry (BRIDGE): study protocol for a randomized controlled trial of a bridge clinic compared with usual care for patients with opioid use disorder. Trials 2021;22(1):757.
Miotto 2012 {published data only}
    1. Miotto K, Hillhouse M, Donovick R, Cunningham-Rathner J, Charuvastra C, Torrington M, et al. Comparison of buprenorphine treatment for opioid dependence in 3 settings. Journal of Addiction Medicine 2012;6(1):68-76.
NCT04139213 {unpublished data only}
    1. NCT04139213. Medication maintenance therapy in community pharmacy settings [Comparing medication maintenance in comprehensive community and pharmacy settings to enhance engagement]. https://clinicaltrials.gov/study/NCT04139213 (first posted 25 October 2019).
Roux 2012 {published data only}
    1. Roux P, Michel L, Cohen J, Mora M, Morel A, Aubertin JF, et al. Methadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trial. BMC Public Health 2012;12:488.
Socias 2022 {published data only}
    1. Socias ME, Wood E, Le Foll B, Lim R, Choi JC, Mok WY, et al. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of Canadian treatment trial. Addiction 2022;117(10):2662-72.
Wartko 2022 {published data only}
    1. Wartko PD, Qiu H, Idu AE, Yu O, McCormack J, Matthews AG, et al. Baseline representativeness of patients in clinics enrolled in the primary care opioid use disorders treatment (PROUD) trial: comparison of trial and nontrial clinics in the same health systems. BMC Health Services Research 2022;22(1):1593.
Watkins 2017 {published data only}
    1. Watkins KE, Ober AJ, Lamp K, Lind M, Setodji C, Osilla K, et al. Collaborative care for opioid and alcohol use disorders in primary care: the SUMMIT randomized clinical trial. JAMA Internal Medicine 2017;177(10):1480-8.

References to studies awaiting assessment

Drucker 2000 {published data only}25760327
    1. Drucker E, Hartel D, Tuchman E. Office-based methadone prescribing in primary care: preliminary results of a randomized clinical trial of safety and efficacy. In: 62nd Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc.; 2000 Jun 17-22; San Juan (Puerto Rico). 2000. [CRIS ID: 25760327]
Ling 2001 {published data only}25760341
    1. Ling W, Cunningham-Rathner J, Miotto K, Cantu CL, Pearce V, Maya S, et al. Treatment settings in evaluation of buprenorphine/naloxone combination tablet for the treatment of opiate dependence. In: 63rd Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc.; 2001 Jun 16-21; Scottsdale (Arizona). 2001. 25760341

Additional references

AAFP 2025
    1. American Academy of Family Physicians. Primary care. https://www.aafp.org/about/policies/all/primary-care.html (accessed 14 May 2025).
APA 2013
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (Virginia): American Psychiatric Association, 2013.
Billock 2023
    1. Billock RM, Steege AL, Miniño A. Drug overdose mortality by usual occupation and industry: 46 US states and New York City, 2020. National Vital Statistics Reports 2023;72(7):1-34.
Bruneau 2018
    1. Bruneau J, Ahamad K, Goyer MÈ, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. Canadian Medical Association Journal 2018;190(5):E247-57.
CDC 2025
    1. Centers for Disease Control and Prevention. CDC reports nearly 24% decline in US drug overdose deaths; 25 February 2025. https://www.cdc.gov/media/releases/2025/2025-cdc-reports-decline-in-us-d... (accessed 27 March 2025).
Chiu 2024
    1. Chiu K, Sud A. Reframing conceptualizations of primary care involvement in opioid use disorder treatment. BMC Primary Care 2024;25(1):356. [DOI: 10.1186/s12875-024-02607-x] - DOI
CIHI 2025
    1. Canadian Institute for Health Information. Primary care. https://www.cihi.ca/en/topics/primary-care (accessed 14 May 2025).
European Union Drugs Agency 2025
    1. European Union Drugs Agency. Drug-induced deaths — the current situation in Europe (European Drug Report 2024). https://www.euda.europa.eu/publications/european-drug-report/2024/drug-i... (accessed 26 March 2025).
EuroQol Group 1990
    1. EuroQol Group. EuroQol — a new facility for the measurement of health-related quality of life. Health Policy 1990;16(3):199-208.
Government of Canada 2025
    1. Government of Canada. About opioids. https://www.canada.ca/en/health-canada/services/opioids/about-opioids.html (accessed 27 March 2025).
Gowing 2011
    1. Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systematic Reviews 2011, Issue 8. Art. No: CD004145. [DOI: 10.1002/14651858.CD004145.pub4] - DOI
Gowing 2017
    1. Gowing L, Ali R, White J, Mbewe D. Buprenorphine for managing opioid withdrawal. Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No: CD002025. [DOI: 10.1002/14651858.CD002025.pub5] - DOI
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al, GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
Higgens 2018
    1. Higgens C, Smith BH, Matthews K. Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis. British Journal of Anaesthesia 2018;120(6):1335-44.
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from https://www.cochrane.org/authors/handbooks-and-manuals/handbook/archive/....
Higgins 2024
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024. Available from https://www.cochrane.org/handbook.
Jannetto 2021
    1. Jannetto PJ. The North American opioid epidemic. Therapeutic Drug Monitoring 2021;43(1):1-5. [DOI: 10.1097/FTD.0000000000000817] - DOI
Jones 2023
    1. Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Network Open 2023;6(8):e2327488. [DOI: 10.1001/jamanetworkopen.2023.27488] - DOI
Korownyk 2019
    1. Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, et al. Managing opioid use disorder in primary care: PEER simplified guideline. Canadian Family Physician 2019;65(5):321-30.
Krausz 2021
    1. Krausz RM, Westenberg JN, Ziafat K. The opioid overdose crisis as a global health challenge. Current Opinion Psychiatry 2021;34:405-12. [DOI: 10.1097/YCO.0000000000000712] - DOI
Larney 2023
    1. Larney S, Jones NR, Hickman M, Nielsen S, Ali R, Degenhardt L. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002–17. Addiction 2023;118:1527-39. [DOI: 10.1111/add.16178] - DOI
Larochelle 2018
    1. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Annals of Internal Medicine 2018;169(3):137-45. [DOI: 10.7326/M17-3107] - DOI
Lefebvre 2024
    1. Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Marshall C, et al. Chapter 4: Searching for and selecting studies (chapter last updated September 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024. Available from https://www.cochrane.org/handbook.
Mattick 2009
    1. Mattick R, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus non opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD002209. [DOI: 10.1002/14651858.CD002209.pub2] - DOI
Mattick 2014
    1. Mattick R, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No: CD002207. [DOI: 10.1002/14651858.CD002207.pub4] - DOI
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine 2009;6(7):e1000097.
Pearce 2020
    1. Pearce LA, Min JE, Piske M, Zhou H, Homayra F, Slaunwhite A, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ 2020;368:m772. [DOI: 10.1136/bmj.m772] - DOI
Platt 2017
    1. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No: CD012021. [DOI: 10.1002/14651858.CD012021.pub2] - DOI
Public Health Agency of Canada 2025
    1. Public Health Agency of Canada. Substance-related Overdose and Mortality Surveillance Task Group on behalf of the Council of Chief Medical Officers of Health. https://health-infobase.canada.ca/substance-related-harms/opioids-stimul... (accessed 26 March 2025).
Raistrick 1994
    1. Raistrick D, Bradshaw J, Tober G, Weiner J, Allison J, Healey C. Development of the Leeds Dependence Questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction 1994;89(5):563-72.
RevMan 2024 [Computer program]
    1. Review Manager (RevMan). Version 7.12.0. The Cochrane Collaboration, 2024. Available at https://revman.cochrane.org.
Russell 2022
    1. Russell C, Lange S, Kouyoumdjian F, Butler A, Ali F. Opioid agonist treatment take-home doses ('carries'): are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA? Harm Reduction Journal 2022;19(1):89. [DOI: 10.1186/s12954-022-00671-z] - DOI
Santo 2021
    1. Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry 2021;78(9):979-93. [DOI: 10.1001/jamapsychiatry.2021.0976] - DOI
Spencer 2024
    1. Spencer MR, Garnett MF, Miniño AM. Drug overdose deaths in the United States, 2002–2022. Hyattsville (MD): National Center for Health Statistics; 2024 March. NCHS Data Brief, no 491. [DOI: 10.15620/cdc:135849] - DOI
WHO 2025
    1. World Health Organization. Primary health care. https://www.who.int/news-room/fact-sheets/detail/primary-health-care (accessed 27 March 2025).
WHO/UNICEF 2025
    1. World Health Organization, UNICEF. A vision for primary health care in the 21st century. https://www.who.int/docs/default-source/primary-health/vision.pdf (accessed 27 March 2025).
WHO/UNODC 2025
    1. World Health Organization, United Nations Office on Drugs and Crime. International standards for the treatment of drug use disorders. https://www.who.int/publications/i/item/international-standards-for-the-... (accessed 14 May 2025).

References to other published versions of this review

Perry 2020
    1. Perry D, Korownyk CS, Ton J, Kirkwood JE, Garrison SR. Primary care versus specialty care management of opioid use disorder. Cochrane Database of Systematic Reviews 2020, Issue 7. Art. No: CD013672. [DOI: 10.1002/14651858.CD013672] - DOI

MeSH terms

Associated data

LinkOut - more resources